Interaction of Helicobacter pylori (Hp) and nonsteroidal anti-inflammatory drugs (NSAID) on gastric mucosa and risk of ulcerations

Medical Science Monitor

Volumn 8, Issue 9, 2002, Pages

  Konturek, Peter C ^a   Konturek, Stanisław J ^a   Cześnikiewicz, Marta ^a   Płonka, Małgorzata ^a   Bielański, Władysław ^a  

^a University Med Collage   (Poland)

Author keywords

Aspirin; Helicobacter pylori; Non steroidal anti inflammatory drugs; Peptic ulcer

Indexed keywords

CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE;

DYSPEPSIA; ENDOSCOPY; ERADICATION THERAPY; GASTRODUODENAL ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PROSTAGLANDIN SYNTHESIS; REVIEW; RISK FACTOR; STOMACH HEMORRHAGE; STOMACH MUCOSA; STOMACH PERFORATION; STOMACH ULCER; ULCER HEALING; ULCEROGENESIS; UREA BREATH TEST;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTRIC ACID; GASTRIC MUCOSA; HELICOBACTER PYLORI; HUMANS; MODELS, BIOLOGICAL; PEPTIC ULCER; RISK FACTORS; STOMACH;

EID: 18744417853     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Konturek PC, Bielanski W, Konturek SJ, et al.: Helicobacter pylori associated gastric pathology. J Physiol Pharmacol, 1999; 50: 695-710
2. Stein M, Rappuoli R, Covacci A: Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci USA, 2000; 97: 1263-1268
3. Odenbreit S, Puls J, Sedlmaier B et al: Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science, 2000; 287: 1497-1500
4. Asahi M, Azuma T, Ito S et al.: Helicobacter pylori Cag A protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med, 2000; 191: 593-602
5. Covacci A, Rappuoli R: Tyrosine-phosphorylated bacterial proteins: "Trojan horses' for the host cell. J Exp Med, 2000; 191: 587-592
6. Li SD, Kersulyte D, Lindley IJ et al: Multiple genes in the left half of the cag pathogenicity island if Helicobacter pylori are required for tyrosine kinase-dependent transcription of interleukin-8 in gastric epithelial cells. Infect. Immunology, 1999; 67: 3893-3899
7. Fallone CA, Barkun AN, Gottke MU et al: Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. Am J Gastroenterol, 2000; 95: 659-669
8. Ji X, Fernandez T, Burroni D et al: Cell specificity of Helicobacter pylori cytotoxin is determined by a short region in the polymorphic midregion. Infect Immun, 2000; 68: 3754-3757
9. El Omar EM, Carrington M, Chow WH et al: Interleukin-1 polymorphisms associated with an increased risk for the development of gastric cancer. Nature, 2000; 404: 398-402
10. Bourke B, Jones NL: Pathogenesis or Helicobacter pylori infection. Curr Opin Gastroenterol, 2001; 17: 24
11. Fiorucci S, Antonelli E, Santucci L et al: Gastrointestinal safety of nitric oxide derived aspirin as related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology, 1999; 116: 1089-1106
12. Konturek SJ, Konturek PC, Plonka M et al: Implication of gastrin in cyclooxygenase-2 expression in Helicobacter pylori infected gastric ulceration. Prostaglandins Other Lipid Mediat, 2001; 66: 39-51
13. Konturek PC, Bobrzynski A, Konturek SJ et al: Epidermal growth factor and transporting growth factor alpha in duodenal ulcer and non-ulcer dyspepsia patients before and after Helicobacter pylori eradication. Scand J Gastroenterol, 1998; 33: 143-151
14. Wallace JL: Nonsteroidal anti-inflammatory drugs and gastropathy: the second hundred years. Gastroenterology, 1997; 112: 1000-1016
15. Wallace JL, Keenan CM, Granger DN: Gastric ulceration-induced by nonstroidal anti-inflammatory drugs is a ueutrophil-dependent process. Am J Physiol, 1990; 259: G462-G467
16. Wallace JL, Tigley AW: Review article: new insights into prostaglandins and mucosal defence. Aliment Pharmacol Ther, 1995; 9: 227-235
17. Kitahora T, Guth P: Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. Gastroenterology, 1987; 114: 93: 810-817
18. Peleg II, Wilcox CM: Role of eicosanoids, cyclooxgenases, and nonsteroidal antiinflammatory drugs in colorectal tumorigenesis and chemoprevention. J Clin Gastroenterol, 2002; 34(2): 117-125
19. Cohn SM, Schloemann S, Tessner T et al: Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthetized though clclooxygenase-1. J Clin Invest, 1997; 99: 1367-1379
20. Davies R, Rampton DS: Eicosanoids role gastrointestinal inflammation and cancer. Eur J Gastroenterol Hepatol, 1997; 19: 1033-1044
21. Wallace JL: NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 2002; 119: 706-714
22. Brzozowski T, Konturek PC, Konturek SJ et al.: Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-refusion induced gastric lesions. Eur J Pharmacol, 1999; 385: 47-61
23. Brzozowski T, Konturek PC, Konturek SJ, et al: Classic NSAIDs and selective cyclooxygenase (COX-1) and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech, 2001; 53: 343-353
24. Hla T, Bishop-Bailey D, Liu CH et al: Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol, 1999; 31: 551-552
25. Lipsky PE, Brooks P, Crofford LJ et al: Unresolved issues in the role of cyclooxygenase-2 in normal physiological processes and disease. Arch Intern Med, 2000; 160: 913-920
26. Lambeau G, Lazdunski M: Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol Sci, 1999; 20: 162-170
27. Langenbach R, Loftin C, Lee C et al: Cyclooxygenase knockout mice: models for elucidating isoform-specific function. Biochem Pharmacol, 1999; 58: 1237-1247
28. Gierse JK, Hauser SD, Creely DP et al: Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J, 1995; 305: 479-484
29. Laine L, cominelli F, Sloane R et al: Interaction of NSAIDs and Helicobacter pylori on gastroduodenal injury and prostaglandin production: A controlled double-blind trial. Ailment Pharmacol Ther, 1995; 9: 127-135
30. Chan FK, To KF, Ng YP et al: Expression of cellular localization of COX-1 and -2 in Helicobacter pylori gastritis. Aliment Pharmacol ther, 2001; 15: 87-193
31. Hawkey CJ, Karrasch JA, Szczepanski L et al: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID- induced Ulcer Managements (OMNIUM) Sutdy Group. N Eng J Med, 1998; 338: 727-734
32. Konturek SJ, Bielanski W, Plonka M et al: Helicobacter pylori infection, non-steroidal anti-inflammatory drugs and smoking in risk of gastro-duodenal ulcers. Screening study in consecutive patients. Digestion, 2002; (in press).
33. Huang JQ, Sridhar S, Hunt RH: Rule of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet, 2002; 359: 14-22
34. Hawkey GJ, Tulassay Z, Szczepańiski L et al: Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet, 1998; 352: 1016-1021
35. Weeks DL, Eskaudari S, Scott DR et al: A H +-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science, 2002; 287: 482-485
36. Rektorschek M, Buhmann A, Weeks D et al: Acid resistance of Helicobacter pylori depends on the Urel membrane protein and an inner membrane proton barrier. Mol Microbiol, 2000; 36: 141-152
37. Konturek PC, Brzozowski T, Meixner H et al: Influence of bacterial lipopolysaccharides on healing of chronic experimental ulcers in rats. Scand J Gastroneterol, 2001; 136: 1239-1247
38. Wang G, Ge Z, Rasko DA et al.: Lewis antigens in Helicobacter pylori: biosynthesis and phase variation. Mol Microbiol, 2000; 36: 1187-1196
39. Zevering Y, Jacob L, Meyer TF: Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development. Gut, 1999; 45: 465-474
40. Israel DA, Peek RM: Review article: pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther, 2001; 15: 1271-1290
41. Blaser MJ: Linking Helicobacter pylori to gastric cancer. Nat Med, 2000; 6: 376-377
42. Shirin H, Moss SF: Helicobacter pylori induced apoptosis. Gut, 1998; 43: 592-594
43. Jones NL, Day AS, Jennings HA et al: Helicobacter pylori induces gastric epithelial cell apoptosis in association with increased Fas receptor expression. Infect Immun, 1999; 67: 4237-4242
44. Houghton J, Macera-Bloch LS, Harrison L et al: Tumor necrosis factor alpha and interleukin 1 beta up-regulate gastric mucosal Fas antigen expression in Helicobacter pylori infection. Infect Immun, 2000; 68: 1189-1195
45. Rudi J, Kuck D, Strand S et al: Involvement of the CD95 (APO-I Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Invest, 1998; 102: 1506-1514
46. Craig PM, Territo MC, Karnes WL et al: Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils. Gut, 1992; 33: 1020-1023
47. Crabtree JE, Wyatt JI, Trejdosiewicz LK et al: Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J Clin Pathol, 1994; 47: 61-66
48. Taha AS, Sturrock RD, Russel RI: Mucosal erosions in longterm non-steroidal anti-inflammatory dug users: predisposition to ulceration and relation to Helicobacter pylori. Gut, 1995; 36: 334-336
49. Gerkens JF, Shand DG, Flexner C et al: Effect of indomethacin and aspirin on gastric blood flow and acid secretion. J Pharmacol Exp Ther, 1977; 203: 646-652
50. Ligumsky M, Golanska EM, Hansen DG, et al: Aspirin can inhibit gastric micosal cydooxygenase without causing lesions in rat. Gastroenterology, 1983; 84: 756-761
51. De Witte TJ, Geerdink PJ, Lamers CB et al: Hypochlorhydria and hypergastrinaemia in rheumatoid gastritis. Ann Rheum Dis, 1979; 38: 14-17
52. Ekstrom P, Carling L, Wetterhus S et al: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic Multicentre Study. Stand J Gastroenterol, 1996; 31: 753-758
53. Gillen D, Wirz AA, Neithercut WD et al: Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut, 1999; 44: 468-475
54. Yeomans ND, Tulassay Z, Juhasz L et al: A comparison of omeprazole with ranitidine for ulcers asssociated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med, 1998; 338: 719-726
55. Misciagna G, Cisternino AM, Freundenhein J: Diet and duodenal ulcer. Dig Liver Dis, 2000; 32: 468-472
56. Bobrzyński A, Bȩben P, Budzyński A et al: The incidence of complications in patients with Helicobacter pylori (Hp) infection and/or NSAID use in the era of Hp eradication. Med Sci Monit, 2002; 8(8): CR554-557
57. Xia HH, Wong BC, Wong KW et al: Clinical and endoscopic characteristics of non Helicobacter pylori, non-NSAID duodenal ulcers: a long term prospective study. Aliment Pharmacol Ther, 2001; 15: 1875-1882